Novan, Inc. (NOVN)
Chart Events
Performance Outlook
| Previous Close | 1.8600 |
| Open | 1.9400 |
| Bid | 1.9000 x 900 |
| Ask | 1.9100 x 900 |
| Day's Range | 1.9000 - 1.9400 |
| 52 Week Range | 1.6700 - 8.1970 |
| Volume | |
| Avg. Volume | 174,985 |
| Market Cap | 36.127M |
| Beta (5Y Monthly) | 0.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2960 |
| Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.00 |
- GlobeNewswire
EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference
– New data analysis from previously completed successful Phase 3 study1 demonstrated WYNZORA® Cream to be effective and convenient for skin of color patients for the treatment of plaque psoriasis DURHAM, N.C. and COPENHAGEN, Denmark, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, a Novan Company, and MC2 Therapeutics presented data from a previously unpublished subgroup analysis of the U.S. Phase 3 pivotal study of WYNZO
- Zacks Small Cap Research
NOVN: EPI Revenue Trends Are Strong
By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT Second Quarter 2022 Results On August 11, 2022, Novan Inc. (NASDAQ:NOVN) reported second quarter financial and operational results in a press release and the filing of Form 10-Q . A conference call and webcast were subsequently held to update investors on recent developments. The call highlighted the performance of the EPI
- GlobeNewswire
Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update
– Total revenue of $6.2 million for the second quarter 2022 – – Activities on track for submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeting submission before the end of 2022 – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the second quarter ended June 30, 2022 and provided a corporate update. The C
